- For Patients
- Introduction to the Marshall Protocol
-
Length of the MP - Immunopathology
- Managing Immunopathology
- Food and Drink
- Light Restriction
- Suitability of the Marshall Protocol
- Starting the Marshall Protocol
- Working with a Physician
- Phase One Guidelines
- Phase Two/Three Guidelines
- Palliative vs. Curative Treatments
- Patient Interviews on Bacteriality
- Non-MP Treatments
- Glossary
- For Physicians
- Publications and Presentations
- Science Behind Marshall Protocol
- Science Behind Immunopathology
- Science Behind Olmesartan (Benicar)
- Safety of Olmesartan (Benicar)
- Safety of MP Antibiotics
- Phase One Guidelines
- Phase Two/Three Guidelines
- Suitability of the Marshall Protocol
- Physicians' Concerns About the MP
- Notice for Emergency Medical Personnel
- For Researchers
- Publications and Presentations
- Science Behind Marshall Pathogenesis
- Science Behind Vitamin D
- Molecular Activity of Vitamin D and the VDR in Chronic Disease
- Th1 Spectrum Disorder – how chronic inflammatory diseases are related
- Transmission of Bacteria and Onset of Chronic Disease
- Pea Soup, Successive Infection, and Variability in Disease
- Evolutionary Perspective on Chronic Disease
- Incidence and Prevalence of Chronic Disease
- Evidence that Chronic Disease Is Caused by Pathogens
- Diseases
- About ARF
- Related Sites
Table of Contents
Marshall Protocol
The PDF form of the most up to date protocol Guidelines are at these links:
Resources for physicians
Resources for patients
Notes and comments
- Legacy content
References
home/mp.txt · Last modified: 01.29.2010 (external edit)
© 2010, Autoimmunity Research Foundation. All Rights Reserved.
